Loading...

APC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
Rb6-8C5_APC_Ly-6GslashLy-6C_Antibody_1_FC_090116
C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C APC (clone RB6-8C5, filled histogram) or APC Rat IgG2b, κ isotype control (open histogram).
  • Rb6-8C5_APC_Ly-6GslashLy-6C_Antibody_1_FC_090116
    C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C APC (clone RB6-8C5, filled histogram) or APC Rat IgG2b, κ isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
108411 25 µg 23€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108412 100 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  2. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  3. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  4. Lim H, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.72. PubMed
  5. Haimon Z et al. 2018. Nature immunology. 19(6):636-644 . PubMed
  6. Gan T, et al. 2019. Front Microbiol. 9:3174. PubMed
  7. Tong CF, et al. 2018. Am J Physiol Cell Physiol. 315:C409. PubMed
  8. Dzhagalov I, et al. 2007. Blood . 109:1620. PubMed
  9. Gerlach BD, et al. 2021. Cell Metab. 33:2445. PubMed
  10. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  11. Tan YY, et al. 2022. Bio Protoc. 12:e4307. PubMed
  12. Poh AR, et al. 2022. Sci Adv. 8:eabl7882. PubMed
  13. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  14. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  15. Wang D, et al. 2023. J Exp Clin Cancer Res. 42:26. PubMed
  16. Chen Y, et al. 2023. Stem Cells Int. 2023:7482546. PubMed
  17. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  18. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  19. Leick MB, et al. 2022. Cancer Cell. 40:494. PubMed
  20. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  21. He Y, et al. 2023. Biomolecules. 13:. PubMed
  22. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  23. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  24. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  25. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  26. Kaku H, et al. 2014. J Immunol. 193:5904. PubMed
  27. Zhou W, et al. 2019. Cell Syst. 0.597916667. PubMed
  28. Mollaoglu G et al. 2018. Immunity. 49(4):764-779 . PubMed
  29. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  30. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  31. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  32. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  33. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  34. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  35. Ma C, et al. 2012. J Leukoc Biol. 92:1199. PubMed
  36. Zhu H, et al. 2018. Elife. 7:. PubMed
  37. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
  38. Götz P, et al. 2022. Int J Mol Sci. 23:. PubMed
  39. Yuan Q, et al. 2021. Cell Reports. 34(5):108724. PubMed
  40. Zhao J, et al. 2020. Pharmacol Res Perspect. 8:e00660. PubMed
  41. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  42. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed
  43. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  44. Sun Y et al. 2018. Cancer cell. 34(4):643-658 . PubMed
  45. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  46. Gu T, et al. 2021. Front Immunol. 11:621441. PubMed
  47. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  48. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  49. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  50. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  51. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  52. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  53. Konishi H, et al. 2020. EMBO J. 39:e104464. PubMed
  54. Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed
  55. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  56. Tamura M, et al. 2019. Sci Rep. 9:8171. PubMed
  57. Gunn BM et al. 2018. Cell host & microbe. 24(2):221-233 . PubMed
  58. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  59. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  60. Distel E, et al. 2014. Circ Res . 115:759. PubMed
  61. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  62. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  63. Parada-Kusz M, et al. 2018. Dis Model Mech. 11:. PubMed
  64. Zeng J, et al. 2019. Cell Rep. 27:549. PubMed
  65. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  66. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  67. Koujah L, et al. 2021. Ocul Surf. 21:238. PubMed
  68. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  69. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  70. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  71. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  72. Yu VWC, et al. 2017. Cell. 168:944. PubMed
  73. Abraham TS, et al. 2019. J Immunol. 202:1301. PubMed
  74. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  75. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  76. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  77. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  78. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  79. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  80. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
  81. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  82. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  83. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  84. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  85. Tavakol DN, et al. 2021. Curr Protoc. 1:e275. PubMed
  86. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  87. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  88. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  89. Cho K, et al. 2021. iScience. 24:103117. PubMed
  90. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  91. Chen X, et al. 2016. PLoS One. 11:e0168861. PubMed
  92. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  93. Jonas B, et al. 2016. PLoS One. 11: 0159189. PubMed
  94. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  95. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  96. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  97. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
  98. Galle-Treger L, et al. 2020. J Allergy Clin Immunol. 145:502. PubMed
  99. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  100. Agelidis A, et al. 2021. JCI Insight. 6: . PubMed
  101. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  102. Gao Y, et al. 2020. Immunity. 52(6):1007-1021.e8. PubMed
  103. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  104. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  105. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  106. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  107. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  108. Ouyang L, et al. 2016. Sci Rep. 6:39541. PubMed
  109. Lu W, et al. 2016. PLoS One. 11: 0149543. PubMed
  110. Winchell CG, et al. 2020. Front Immunol. 1.077083333. PubMed
  111. Yu JM, et al. 2019. Nat Commun. 4.388888889. PubMed
  112. Okwan–Duodu D, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1125. PubMed
  113. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  114. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  115. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  116. Kandasamy M, et al. 2013. PLoS Pathog. 9:e1003115. PubMed
  117. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  118. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  119. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  120. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  121. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  122. Siddique SM, et al. 2019. Sci Rep. 9:13977. PubMed
  123. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  124. Pattabiraman D, et al. 2009. Mol Cancer Res. 1.317361111. PubMed
  125. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  126. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  127. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  128. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  129. Skucha A, et al. 2018. Nat Commun. 9:1983. PubMed
  130. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  131. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  132. Hu R, et al. 2015. J Immunol. 195: 4802 - 4809. PubMed
  133. Asada S, et al. 2018. Nat Commun. 9:2733. PubMed
  134. Weckbach LT, et al. 2019. J Exp Med. 216:350. PubMed
  135. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  136. Nguyen GT, et al. 2020. eLife. 9:e56656.. PubMed
  137. Matsumoto M, et al. 2008. J Immunol. 181:3628. PubMed
  138. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  139. Iwai H, et al. 2015. Tuberculosis (Edinb). 95:246. PubMed
  140. Qiu X, et al. 2009. Infect Immun. 77:85. PubMed
  141. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  142. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  143. Fielding C, et al. 2022. Nat Commun. 13:543. PubMed
  144. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  145. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  146. Collins C, et al. 2014. Proc Natl Acad Sci U S A. 111:9899. PubMed
  147. Hussein M, et al. 2015. PLoS One. 10: 0135218. PubMed
  148. Vannini N, et al. 2016. Nat Commun. 7:13125. PubMed
  149. Stone S et al. 2018. Glia. 66(7):1331-1345 . PubMed
  150. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  151. Zeng F, et al. 2021. J Invest Dermatol. 596:141. PubMed
  152. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  153. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
  154. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  155. Wang X, et al. 2018. Front Immunol. 9:2615. PubMed
  156. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  157. Schmidts A, et al. 2020. J Immunother Cancer. 8:. PubMed
  158. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  159. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  160. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
RRID
AB_313376 (BioLegend Cat. No. 108411)
AB_313376 (BioLegend Cat. No. 108412)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark PLUS UV395™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Red™ 718 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Spark Blue™ 574 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Go To Top Version: 3    Revision Date: 09/01/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account